SEC Form 4	
------------	--

FORM 4

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number:

Estimated average burden hours per response: 05

Instruction 1(I	b).		Filed pursuant to Section 16(a) of the Securities Exchange Act of 19			0.5		
			or Section 30(h) of the Investment Company Act of 1940	-				
1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol Enliven Therapeutics, Inc. [ELVN]		ationship of Repo k all applicable)	Reporting Person(s) to Issuer ble)		
Kintz Samı				1	Director	10% Ow	ner	
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/25/2024	1	Officer (give tit below)	le Other (sp below)	pecify	
	N THERAPEU	JTICS, INC.	0//25/2024		PRESIDE	SIDENT AND CEO		
6200 LOOKOUT ROAD			4. If Amendment, Date of Original Filed (Month/Day/Year)	ay/Year) 6. Individual or Joint/Group Filing (Check Applicab Line)				
(Street)				1	Form filed by C	One Reporting Person	n	
BOULDER	СО	80301			Form filed by N Person	Nore than One Repor	ting	
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication					
			Check this box to indicate that a transaction was made pursuar satisfy the affirmative defense conditions of Rule 10b5-1(c). Se	nt to a contra e Instruction	act, instruction or w n 10.	ritten plan that is intend	ded to	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			
Common Stock	07/25/2024		S ⁽¹⁾		3,793	D	\$24.53 ⁽²⁾	1,071,732	Ι	See footnote ⁽³⁾	
Common Stock	07/25/2024		S ⁽¹⁾		8,164	D	\$ 25.1004 ⁽⁴⁾	1,063,568	Ι	See footnote ⁽³⁾	
Common Stock	07/25/2024		S ⁽¹⁾		43	D	\$25.8295 ⁽⁵⁾	1,063,525	Ι	See footnote ⁽³⁾	
Common Stock								88,531	Ι	See footnote ⁽⁶⁾	
Common Stock								88,531	Ι	See footnote ⁽⁷⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Expira		6. Date Exerc Expiration Da (Month/Day/h	7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

2. This transaction was executed in multiple trades at prices ranging from \$23.81 to \$24.8005. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. 3. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

4. This transaction was executed in multiple trades at prices ranging from \$24.81 to \$25.7811. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. 5. This transaction was executed in multiple trades at prices ranging from \$25.8172 to \$25.8413. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. 6. The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's elder son and for which the Reporting Person serves as an investment advisor.

7. The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's younger son and for which the Reporting Person serves as an investment advisor.

/s/ Ben Hohl, by power of attorney

07/29/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.